These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 19724165)

  • 41. [Vascular Calcification - Pathological Mechanism and Clinical Application - . Bisphosphonates for vascular calcification].
    Kurozumi A; Okada Y; Nakano K; Tanaka Y
    Clin Calcium; 2015 May; 25(5):723-8. PubMed ID: 25926576
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Bisphosphonates and atherosclerosis: why?
    Bevilacqua M; Dominguez LJ; Rosini S; Barbagallo M
    Lupus; 2005; 14(9):773-9. PubMed ID: 16218486
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Bisphosphonates and atherosclerosis: why?
    Ylitalo-Heikkala R
    Lupus; 2006; 15(12):903. PubMed ID: 17212001
    [No Abstract]   [Full Text] [Related]  

  • 44. Bisphosphonates beyond their anti-osteoclastic properties.
    Varenna M
    Rheumatology (Oxford); 2014 Jun; 53(6):965-7. PubMed ID: 24273023
    [No Abstract]   [Full Text] [Related]  

  • 45. Extra-skeletal effects of bisphosphonates.
    Corrado A; Santoro N; Cantatore FP
    Joint Bone Spine; 2007 Jan; 74(1):32-8. PubMed ID: 17196868
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Bisphosphonates and bone diseases: past, present and future.
    Heymann D
    Curr Pharm Des; 2010; 16(27):2948-9. PubMed ID: 20722613
    [No Abstract]   [Full Text] [Related]  

  • 47. Polydatin for treating atherosclerotic diseases: A functional and mechanistic overview.
    Wu M; Li X; Wang S; Yang S; Zhao R; Xing Y; Liu L
    Biomed Pharmacother; 2020 Aug; 128():110308. PubMed ID: 32480216
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Bisphosphonates and atherosclerosis.
    Ylitalo R
    Gen Pharmacol; 2000 Dec; 35(6):287-96. PubMed ID: 11922958
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Disambiguating the bisphosphonates.
    Van den Wyngaert T; Huizing MT; Vermorken JB
    Ann Oncol; 2008 Jul; 19(7):1357-1359. PubMed ID: 18522931
    [No Abstract]   [Full Text] [Related]  

  • 50. Do bisphosphonates and statins have a role in spondyloarthritis management?
    Maksymowych WP
    Curr Rheumatol Rep; 2008 Oct; 10(5):364-70. PubMed ID: 18817639
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [The bisphosponates: chemical characteristics, skeletal biological effects and extra-skeletal effects].
    Corrado A; Cantatore FP
    Reumatismo; 2005; 57(3):142-53. PubMed ID: 16258598
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Comments on Addolorata Corrado et al. review "Extra skeletal effects of bisphosphonates".
    Singh B; Singh S; Nagraj C
    Joint Bone Spine; 2007 Oct; 74(5):518; author reply 518-9. PubMed ID: 17900960
    [No Abstract]   [Full Text] [Related]  

  • 53. The ODYSSEY Outcomes trial: Clinical implications and exploration of the limits of what can be achieved through lipid lowering.
    Maki KC
    J Clin Lipidol; 2018; 12(5):1102-1105. PubMed ID: 29941396
    [No Abstract]   [Full Text] [Related]  

  • 54. Therapeutic perspectives.
    Fiore CE; Pennisi P; Tinè M
    Clin Cases Miner Bone Metab; 2008 Jan; 5(1):45-8. PubMed ID: 22460845
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Foreword: bisphosphonates.
    Burr D; Russell G
    Bone; 2011 Jul; 49(1):1. PubMed ID: 21665184
    [No Abstract]   [Full Text] [Related]  

  • 56. Correlation research between osteoporosis and left ventricular hypertrophy in older men.
    Huang C; Li S
    Arch Med Sci; 2016 Dec; 12(6):1220-1224. PubMed ID: 27904511
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Risk of cardiac valvulopathy with use of bisphosphonates: a population-based, multi-country case-control study.
    Coloma PM; de Ridder M; Bezemer I; Herings RM; Gini R; Pecchioli S; Scotti L; Rijnbeek P; Mosseveld M; van der Lei J; Trifirò G; Sturkenboom M;
    Osteoporos Int; 2016 May; 27(5):1857-67. PubMed ID: 26694594
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Osteoporosis Is Associated With High Risk for Coronary Heart Disease: A Population-Based Cohort Study.
    Chen SJ; Lin CS; Lin CL; Kao CH
    Medicine (Baltimore); 2015 Jul; 94(27):e1146. PubMed ID: 26166125
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Bisphosphonates and risk of cardiovascular events: a meta-analysis.
    Kim DH; Rogers JR; Fulchino LA; Kim CA; Solomon DH; Kim SC
    PLoS One; 2015; 10(4):e0122646. PubMed ID: 25884398
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Bisphosphonates reduced the risk of acute myocardial infarction: a 2-year follow-up study.
    Kang JH; Keller JJ; Lin HC
    Osteoporos Int; 2013 Jan; 24(1):271-7. PubMed ID: 23152093
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.